Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy. Hong SJ, Zenger C, Pecoriello J, Pang A, et al. Inflamm Bowel Dis 2022;28:1826-1832.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hong SJ, Zenger C, Pecoriello J, Pang A, et al. Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy. Inflamm Bowel Dis 2022;28:1826-1832.
PMID: 35262671